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ABSTRACT 
 
Aim. To evaluate four years of preoperative lymphoscintigraphy experience, as well as 
accuracy of SN biopsy performed in our institution in melanoma patients with various tumor 
thicknesses. Also, the aim was to evaluate the recurrence rate related to pathohistological 
findings.  
Methods and Patients. Two hundred and one patients underwent sentinel node biopsy from 
February 2002 to November 2005.  Lymphoscintigraphy for identification of sentinel nodes 
was performed four to six hours prior to operation of the patient. Sentinel lymph node biopsy 
using intraoperative hand-held gamma probe was performed in all patients, as well as wide 
local excision of biopsy wound or primary lesion (N=56). Immediate complete basin 
dissection was performed in patients with sentinel node metastases. In four patients delayed 
complete lymph node dissection was performed due to definitive histopathologic examination 
of sentinel node. The accuracy of sentinel node biopsy was determined by comparing the 
intraoperative rates of sentinel node identification and the subsequent development of nodal 
metastases in regional nodal basins of patients with tumor negative sentinel node and in those 
with tumor positive sentinel node. 
Results. By preoperative lymphoscintigraphy we identify sentinel node in all but one patient 
(99.0%). In 248 nodal basins (1.2/patient) 372 sentinel nodes (1.52 sentinel/basin; 1.8 
sentinel/patient) were observed. The highest number of sentinel nodes was noticed in the 
groin of patients with melanoma on lower extremities (1.5/patient), followed by axilla with 
1.3 per patient. Anomalous lymphatic drainage patterns were observed in 15.0% of all 
patients. Sentinel node identification rate was 99.0% overall; 100% for the groin basins, and 
98.0% for the axilla and head and neck basin. Forty-two patients (20.8%) had tumor positive 
sentinel nodes.  Local or distant recurrences had 10 (5.0%) patients during median follow up 
of 23.1 months (range 2-46 months). The rate of false-negative lymphatic mapping and 
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sentinel node biopsy as measured by nodal recurrence in a tumor-negative SN patients was 
1.3%. During the follow-up period three of 201 patients died due to the other diseases and 
three patients died due to the melanoma metastases, with median follow up of 13.5 months 
(range 12 to 22).  
Conclusion. Preoperative lymphoscintigraphy is sensitive, inexpensive and essential method 
for the identification of drainage basins, determination of number and position of sentinel 
node and its location outside the usual nodal basins. Scintigraphic findings may lead to 
changes in surgical management due to the unpredictability of lymphatic drainage. Low 
incidence of regional disease recurrence in patients with tumor negative sentinel node 
supports the use of preoperative lymphoscintigraphy and sentinel node biopsy as a safe and 
accurate procedure for staging the regional nodal basin in patients with malignant melanoma.  
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INTRODUCTION 
Metastatic melanoma characteristically disseminates in an orderly progression of 
metastatic cells from the primary site through lymphatic vessels to the regional lymph nodes 
and then to more distant sites. The most important prognostic factor of the 5-year survival rate 
is the presence of metastases in regional lymph nodes (1). Also, the tumor thickness and 
ulceration are the dominant predictors of survival in patients with localized melanoma (2). 
Surgical excision is the treatment of choice for primary lesion in all patients and 
complete lymph node dissection is not doubtful in patients with clinically obvious regional 
lymph node metastases. About 80% of patients with intermediate-thickness have tumor-free 
regional nodes and therefore would be unnecessarily placed at risk of complications which 
could arise from the regional lymphadenectomy, such as nerve injury and anesthetic 
complications of elective lymph node dissection, instead of observation after wide excision. 
As a result of recent investigations regarding improved survival in patients with regional 
nodal metastases following treatment with adjuvant interferon or vaccine therapy (3,4), 
accurate staging has become an additional motivation for assessing the regional nodal basin. 
Although some authors (5) reported a low incidence of metastases in thin melanoma (≤1 mm), 
Kalady et al. (6) presented that those melanomas are also potentially lethal lesions with 20% 
risk of disease recurrence, which could also change therapeutic approach in patients with thin 
melanoma.  
 Preoperative lymphoscintigraphy in melanoma has been applied to identify the 
localization of the true nodal drainage basins of lesions situated in regions of highly variable 
drainage, in particular on the trunk, head and neck. Because of the unpredictability of 
lymphatic drainage, preoperative scintigraphic findings may lead to changes in surgical 
management. The sentinel lymph node (SN) is the first lymph node to drain a cutaneous 
lesion, and thereby allows prediction of the metastatic status of the regional lymph node 
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group. The excellent results using sentinel biopsy technique that have been published from 
large and randomized studies (7,8,9) from experienced teams present challenge for smaller 
community like our, therefore we reviewed our results. Lymphoscintigraphy and SN biopsy 
has been adopted in our institution as a standard procedure in management of patients with 
melanoma according to AJCC staging system. 
This study reviewed lymphatic drainage pathways and SNs location by preoperative 
lymphoscintigraphy, as well as accuracy of SN biopsy that has been performed. 201 patients 
with various tumor thicknesses were analyzed and the aim of our study was to evaluate the 
recurrence rate related to the pathohistological findings. 
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PATIENTS AND METHODS 
Patients 
From February 2002 to November 2005, 201 patients with cutaneous melanoma were 
referred to the Department of Oncology and Nuclear Medicine, University Hospital “Sisters 
of Charity” (National Referral Centre for Melanoma) for the preoperative 
lymphoscintigraphy. All patients underwent SN biopsy at the Department of Surgery and at 
the Department for Head and Neck Surgery (thirty patients from the learning phase were not 
included into this study). Dermatologists, surgeons and oncologists made selection for the 
procedure according to AJCC recommendations. The demographic and other clinical 
characteristics of the patients are listed in the Table 1. Lymphoscintigraphy was performed in 
52 patients with primary lesion (proved by patohystological examination after excision and 
SN biopsy) and in 149 patients with biopsy scar after excision of malignant melanoma. All 
patients were candidates for the SN biopsy if there was no evidence of metastatic melanoma 
in regional lymph nodes and/or distant sites by physical examination and staging evaluation 
(ultrasonography of the regional basins and abdominal cavity, chest x-ray, bone scintigraphy, 
tyrosinase and alkaline phosphatase). Patients were regularly followed-up at two, three or six 
month intervals, according to the clinical stage.  
 
Preoperative lymphoscintigraphy   
Lymphoscintigraphy was performed in all patients four to six hours prior to the 
operation, to delineate the lymphatic drainage and mark the location of SNs.  About 18,5-74 
MBq (0.2-0.5 mCi) of commercial 99mTc nanocolloid kit (rhenium sulfide nanocolloid, 
Nanocis, CIS Bio International, France) was prepared for the several intradermal injections 
with a total volume of 0.2-0.5 mL 0.9% saline. The mean diameter of the colloidal particles 
was averagely 100 nm.  
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Immediately after the administration of the radioisotope, scintigraphic dynamic 
acquisition was carried out (10 frames; 60 seconds/image) (Figure 1). Static five-minute 
images (Figure 2) in anterior, posterior and lateral views were performed following dynamic 
study to document the site of the identified sentinel nodes. Dual-head gamma camera 
(Siemens, Multispect, Illinos, USA) with large-field-of-view (matrix size 128x128) was used.  
 Furthermore, the exact location of the SN was preoperatively marked on the overlying 
skin of patients by the nuclear medicine physician, guided with 57Co pen under a gamma 
camera in order to assist the surgeon to locate the SN during biopsy. All registered SNs were 
checked again with hand-held gamma probe (Navigator GPS, Radiation Monitoring Devices 
Inc., Watertown, MA, U.S.A.) and ultrasound (Vision 100, Toshiba, Japan).  
Finally, patients were taken to the operating room for surgery within four to six hours 
following radiotracer injection.  
 
Surgical Technique 
 For the intraoperative identification of SNs after preoperative lymphoscintigraphy 
hand-held gamma probe has been used. The SN was defined as the hottest node underlying 
skin mark, with radioactivity at least 2-3 fold higher than adjacent tissue. The ex-vivo counts 
were also recorded for each removed SN and nodal basin checked again for the radioactivity 
after SNs removal. Nuclear medicine physician was also present in the operating room for the 
first 50 procedures to assist the surgeon in identification of SN radioactivity. 
Wide local wound excision was performed with operative margin 1-2 centimeters from 
primary melanoma biopsy border, depending to melanoma thickness.   
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Histopathologic examination of the sentinel node 
 All removed SNs were sent to pathologist for frozen-section analyses during the 
operation and complete lymph node dissection (CLND) was performed in all patients with SN 
specimens containing tumor and also in those patient without SN identification during biopsy. 
SN was further processed as a paraffin-embedded specimen for definitive diagnosis. 
Specimens were stained with conventional haematoxylin-eosin (H&E) and also paraffin 
blocks were chosen for immunohistochemical staining with monoclonal antibodies for S-100 
and HMB-45. Protocol for pathological examination of SN was changed during the study, 
therefore in the last 156 patients immunohistochemical staining with monoclonal antibodies 
for S-100 was omitted. 
   
Statistical analysis 
Statistical analysis was performed using commercial software package SPSS.
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RESULTS 
Anatomic distribution of the primary lesions is listed in the Table 1. More than half of 
the studied patients have had the truncal melanoma, whereas extremity melanoma was equally 
distributed to upper and lower extremities. Median melanoma thickness was 2.1 mm (range 
0.4-9.0 mm) and median diameter of all lesions was 18 mm (range 4 to 40). Out of all 201 
patients included in the study 57 patients (28.4%) had Breslow thickness I and II (Table 2), 
but at the same time they had Clark level III or more.  
 
Lymphoscintigraphic findings 
SNs  were lymphoscintigraphically visualized in 200 (99.5%) patients and mapping 
failed in only one patient with melanoma on the neck. In 248 nodal basins (1.2/patient) 372 
SNs (1.52 sentinel/basin; 1.8 sentinel/patient) were observed. The highest numbers of SNs 
were noticed in the groins of patients with melanoma of lower extremities (1.5/patient), 
followed by axilla with 1.3 per patient. Anomalous lymphatic drainage patterns were 
observed in 15.0% of all patients.  
Our data showed that one third of melanoma of the head and neck, as well as those 
located on the trunk, drained into more than one lymphatic basins (Table 3). Discordance of 
lymphatic findings compared to the historical anatomical guidelines was found in 39.0% of 
patients with lesions in head and neck regions and in 23.0% of those with trunk lesions. 
Tumors located on the extremities were drained exclusively into one nodal basin. 
 Aberrant lymphatic pattern was noticed in six patients (sentinel appeared in the groin 
and along iliac artery chain, popliteal area, subscapular area, cervical area, intercostals area) 
and one of those patients had also tumor deposits in SN. 
Secondary lymph nodes were especially extensive in patients with primary lesions 
situated on the head. They appeared in all patients minutes following SNs appearance. Median 
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number of secondary lymph nodes was 2.5 (range 2-5) and were registered 15-30 minutes 
from the beginning of imaging.  
 
Surgery identification rate  
 The SN identification by the surgeons was based on the highest level of 
radioactivity measured by the hand-held gamma probe and overall identification rate was 
99.0%. Mapping of groin (100%) or axillary regions (100%) was more successful than 
mapping of cervical area (94.1%) or ectopic drainage sites such as parascapular area (83.3%).  
Tumor-positive lymph node was found in 42 patients (20.8%) and in 42 SNs (11.3%) 
out of 372 lymph nodes analyzed (Table 4). In the group of patients with the melanoma 
thickness less than 1.5 mm 10.5% SN-positive patients were detected (6/57), although 
majority of patients with positive SN had thicker tumor (Table 2).  
Analyses of SN-positive nodal basins demonstrated that there was no difference in the 
number of positive SNs between the patients with drainage to two nodal basins compared to 
one nodal basin (Table 3), although the number of biopted SNs in the group with two nodal 
basins was significantly higher (Chi-Square Test, p=0.045).  
 
Surgical morbidity 
There was no operative mortality. Complications of SN biopsy were rare (seroma and 
hematoma in the region) and observed in 5.2% of patients (11/201 patients). After CLND 
postoperative complications were more frequent, wound infection in two patients (1.0%) and 
seroma in 23.4% of patients (47/201) were registered. Thrombophlebitis developed in one 
patient (0.5%) after CLND and there were no other regional complications. Also, no systemic 
complications were found in our patients.  
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Histopathologic findings 
 All 372 SNs were examined by frozen section and 38 of 42 positive (90.5%) nodes 
were confirmed during operation. Four additional SNs (9.5%) have been confirmed as 
positive on definitive PHD analysis, therefore delayed CLND was performed in those four 
patients.  
Histopathologic reevaluation of SNs specimens from two SN-negative patients with 
recurrences didn’t show any tumor cells in the original SNs specimens. 
 
Patterns of recurrence 
At median follow-up of 23.1 months (range 2 to 46), melanoma had recurred in 10 
(5.0%) of the 201 patients (Table 5). First recurrence was regional in 8 patients and distant 
recurrence occurred in two patients. All regional first recurrences were registered in the SN 
drainage basin, except in one patient with non-sentinel basins recurrence. In a group of SN-
positive patients, one patient developed distant metastases despite of negative in-transit node 
and with no regional basin recurrences. Among other SN-positive patients distant recurrence 
followed regional node recurrence in three patients, but in those patients in-transit metastases 
was not identified. Two patients (1.3%) of the 157 patients with tumor-negative SNs 
developed metastases: one patient had regional nodal recurrence after follow-up of 9.5 months 
and in other patient distant metastases was found without regional nodal involvement after 14 
months of follow-up. This finding also presents the rate of false negative lymphatic mapping. 
 Finally, three patients out of five with distant metastases died at median follow-up of 
13.5 months (range 12 to 22).  Additionally, three patients had died during the follow-up 
period but due to the other diseases. 
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DISCUSSION 
Preoperative lymphoscintigraphic identification of the SN has been very high in our 
study, with accuracy of 99.5%. The efficacy of lymphoscintigraphy could depend on the type 
and preparation of radiopharmaceutical, injection technique and prior surgical intervention. 
We confirmed that we used appropriate radiotracer who is simple for use and with acceptable 
consuming time for preparation.  Different radiotracers are being used for SN mapping and 
their quality was tested in different centers. In our department we use 99mTc nanocolloid 
which is predominant type of radiopharmaceutical used in Europe (10).  Failure to identify a 
lymph drainage pattern or SN visualization has been reported in up to 10% of cases (11), 
predominantly during the implementing of the procedure. In our group of patients, SN was 
not identified in only one patient, probably due to large excision scar. Our experience showed 
that the most important criteria for using an agent are capability of flowing rapidly from the 
injection site through the lymphatic vessels and localizing and retaining within the sentinel 
node. It should also produce high-quality images and deliver the radiation dose as low as 
possible.  
Immediate dynamic imaging study was essential for the proper SN identification, 
especially for those lesions situated on the head, middle of the trunk and around the shoulders. 
Our data showed that sequential imaging was crucial in recognition of interval nodes in four 
patients. Kalady et al. (12) recommended repeated imaging immediately before surgery, 
because they identified additional SNs in 19% of patients at the time. This rule should be 
applicable for patients when lymphoscintigraphy is performing 18 to 24 hours before SN 
biopsy.  
Reliability of lymphoscintigraphy as a method was disputed in several studies 
conducted in early 90-ties. Kapteijin et al. (13) noted that in even 12% of patients the number 
of SNs in the same patient differ on the two studies performed within 2-4 week interval. Also, 
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the study of Norman et al. (14) showed that agreement in SN identification at repeated 
lymphoscintigraphy was 83%, although in the beginning of lymphoscintigraphy 
implementation in the study published 1994 (15), the authors showed high SN identification 
rate by lymphoscintigraphy.  Some lately published studies confirmed favorable results with 
SN identification rate using preoperative lymphoscintigraphy in 96-100% of cases (7,8,16).  
Preoperative lymphoscintigraphy may be also inaccurate when melanomas have been 
resected with large margins (greater than 2.0 cm), especially if the wound was closed with 
rotation flaps and in melanomas located on the head, neck or on the trunk (17).  The failure of 
SN visualization in our study in the patient with excision scar on the mastoid region (after 
three repeated imaging, up to 3 hours post injection), could have been caused by disrupted 
lymphatic drainage after melanoma excision.  
All patients have been operated in our surgical departments and the amount of 
radioactivity injected 4-6 hours before biopsy was sufficient for the intraoperative SN 
detection using only gamma probe (without blue-dye mapping). In one patient out of 201 
radioactivity was not detected after preoperative lymphoscintigraphy at subscapular region.  
We are aware that leading melanoma centers use both blue dye and gamma probe for intra-
operative mapping, but our intra-operative SN identification rate of 99% supports thesis that 
gamma radiation detection could be sufficient for accurate SN biopsy. 
Although majority of the studied patients have had predictable lymphatic drainage on 
the basis of classic anatomic guidelines, we found lymphatic drainage in two or more 
contiguous nodal basins and/or in-transit nodes in 24.0% of patients. Lymphatic drainage was 
unpredictable in some tumors (N=6, 3.0%) and SN situated at unusual place regarding to its 
classic anatomic position (epitrochanteric, subscapular, nuchal etc.), therefore operative 
intervention was changed due to this findings. In one patient with melanoma on head and 
neck SN was not found by preoperative lymphoscintigraphy and in another located on the 
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shoulder intraoperative localization failed. Despite of the fact that the accuracy of SN 
identification was lower at head and neck and trunk lesions comparing to extremity (94% vs. 
100%), we cannot claim that anatomic site make an important difference for the accuracy of 
preoperative lymphoscintigraphy with SN biopsy and/or CLND. Namely, only 3 % of patients 
with unusual drainage pathways were included in our study. Good accuracy in our study may 
lie in fact that in our Center two surgeons treat all melanoma patients and thereby have 
enough experience required for a high degree of mapping accuracy. Also, we believe that 
proper selection of patients for sentinelectomy, which is made by trained specialists from 
Croatian National Melanoma Center including dermatologist, oncologist, nuclear medicine 
specialists and surgeons, was crucial in achieving high accuracy.  
Some controversy also exists over the utility of different methods for intra-operative 
SN evaluation in patients with malignant melanoma.  Because of 59% of sensitivity for FS 
some authors (18) not recommend FS for routine use. On the other side, a group from 
Slovenia (19) recommended use of intra-operative imprint cytology (touch prep) with 46% 
sensitivity as a valuable method for SN evaluation. Our sensitivity of 91% for FS supports FS 
examination as a first method for intra-operative evaluation of SN. Furthermore, we believe 
that recommendations from MSLT-I (7) for co-injection of carbon dye of paraffin-embedded 
SN specimens may further increase accuracy of the technique in patients with tumor-free 
specimens by H&E or immunohistochemical staining. 
In the study of Uren et al. from 2001 (20), 7.2% of interval nodes were found and a 
real validity of this finding was confirmed in lately published studies. Namely, available data 
from Estourgie group (21) showed high incidence of in-transit metastasis and Balch group (2) 
proved that intralymphatic metastases (satellite lesion around a primary melanoma and in-
transit lymph pathway) are associated with poor survival outcomes. In one of our patients 
with distant metastases but initial negative SN, we found no metastatic deposits in in-transit 
 15 
node. One reason for systemic metastasis development without regional/local metastatic 
deposits is hematogeneous tumor cells spread. We found no metastatic cells in in-transit 
lymph nodes in none of four patients, although several studies suggests that selective 
lymphadenectomy could alters the incidence of local/in-transit recurrence (21,22).  A review 
from three leading melanoma centers (23) proved that SN biopsy and CLND in SN-positive 
patients does not increase the incidence of in-transit metastases. 
  Despite of favorable results demonstrated in the data published during last 15 years 
regarding the use of a SN biopsy according to AJCC recommendations, several investigators 
(5,6,8) showed controversies about the indications for SN biopsy. Namely, Kalady et al. (6) 
reported that 10% of their patients with lesions <0.75 mm have had recurrence event within 
fife years. Bleicher et al. (5) found 12% of recurrences in patients with SN metastases and in 
3.7% in those with negative SNs in thin melanomas. They proposed in patients with 
melanomas with thickness between 0.76 and 1.00 mm a case-by-case evaluation for SN 
biopsy, including consideration not only a Clark level, but also the age of patients and positive 
tumor margin after initial biopsies. Considering those findings we performed 
lymphoscintigraphy with SN biopsy in almost one third (28.0%) of patients with melanoma 
thinner than 1.5 mm (Table 2). We found a 10.5% incidence of SN metastases from lesion 
thinner than 1.5 mm, but there were no nodal recurrences in those patients during relatively 
short follow-up. In addition, in the group with SN-negative patients with thin melanoma there 
were no local/regional or systemic recurrences.  
Overall regional nodal and systemic recurrence of 5.0% in our study group during the 
46 months follow-up period is quite similar to other recent published data (22, 24-29).  The 
false negative rate of 1.3% is less than 5% that is generally considered acceptable (28). In the 
future we could expect some additional recurrences in patients with SN-negative and SN-
positive patients, because in previously mentioned studies a median follow-up was much 
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longer than 23.1 months in our study. This number should not be change with increasing case 
volume (7). 
We also consider that the learning period is crucial in establishing lymphoscintigraphy 
and SN biopsy as a standard procedure in treatment of patient with early stage melanoma and 
this is a period for achievement a good collaboration between the different specialists which 
are included in patients management, which could have a large impact on accuracy of method 
as well.  
Conclusions 
Four years of experience in our study of SN biopsy confirmed that preoperative 
lymphoscintigraphy in patients with malignant melanoma is essential to indicate the drainage 
basins, determine the number and the position of SNs and also to locate SNs outside the usual 
nodal basins. Sentinel biopsy comes with low postoperative morbidity of patients and the 
morbidity was not affected by the unusual placement of SN.  
This study supports the use of intraoperative frozen section followed by conventional 
H&E and immunohistocemical analyses for accurate evaluation of the SN regarding 
micrometastases. 
Independently, the low incidence of disease recurrence in patients with tumor negative 
SNs supports the use of preoperative lymphoscintigraphy and SN biopsy as a safe and 
accurate procedure for staging the regional nodal basin.  According to the SN status, patients 
were directed for further treatment and follow-up.   
The main limitations of our study are relatively short follow-up period and that 
subgroup of patients with disease recurrences was not analyzed regarding other known 
prognostic factors such as age and the presence of ulceration. 
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Table 1. Clinical characteristics of patients with melanoma with sentinel node biopsy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics N % 
Gender  
 Male 
 Female 
 
94  
107 
 
46.7 
53.3 
Age (years) 
Median 
Range 
 
54.0 
67.0 
Site of primary tumor  
Head and neck 
Trunk 
Extremity 
  Upper 
   Lower 
 
17        
107 
 
32 
45 
 
8.5 
53.3 
 
15.9 
22.3 
Basins biopted  
   One 
   Two 
   Three 
   Four 
 
142 
52 
6 
1 
 
70.6 
25.1 
3.0 
0.5 
Melanoma thicknes (mm) 
Median 
Range 
 
2.1 
8.6 
Melanoma diameter (mm) 
Median 
Range 
 
18.0 
36.2 
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Table 2. Patient classifications according to Breslow thickness of primary melanoma and 
distribution of sentinel node positive patients by tumor depths. 
 
 
 
 
 
                        Patients Sentinel node positive patients Tumor depths (mm) 
Breslow 
classification N % N % Median Range 
I 15 7.5 2 13.3 0.62 0.60 
 
II 42 20.9 4 9.5 1.14 1.21 
III 53 26.5 8 15.0 2.01 2 
IV 28 13.9 12 42.8 2.98 4  
V 63 31.4 16 25.3 5.02 7.8 
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Table 3. Sentinel node status of melanoma patients in relation to primary tumor location and 
biopsied basins, including in-transit lymph nodes status. 
 
 
 No. of drainage lymphatic basins 
One Two Three Four In-trans 
Sentinele Node Status (SN) Primary tumor site 
* + 
 
♦ 
- + - + - + - + - 
Head/neck 0 8 0 5 1 2  
  
 
Trunk 22 41 8 31 0 3 1 0 0 2 
Upper extremities 3 29         
Lower extremities 7 38       0 2 
Total 32 116 8 36 1 5 1 0 0 4 
 
* + revealed sentinel node positive patients; 
♦
 – revealed sentinel node negative patients.
 24 
Table 4. Distribution of patients who had tumor positive sentinel nodes and patients whose 
melanoma recurred by drainage nodal basins. 
 
 
 
 
 
 
 
 
 
 
Total No.  
of patients 
(N=201) 
Sentinel 
positive 
patients 
(N=42) Sentinel node basin 
N % N % 
Patients with 
disease 
recurrence 
(N=10) 
Axilla 
Groin 
Cervical 
Multiple 
Other* 
84 
45 
17 
49 
6 
41.7 
22.3 
8.5 
24.3 
3.0 
15 
13 
1 
12 
1 
17.8 
28.9 
5.9 
24.5 
20.0 
4 
4 
0 
2 
0 
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Table 5. Incidence of regional or distant melanoma recurrences in relation to sentinel node 
status at patients median follow-up of 23 months. 
 
 
 Sentinel positive 
patients 
(N=42) 
Sentinel negative 
patients 
(N=157) 
Recurrence 
      Local nodal/in-transit 
      Distant  
8 
7 
1 
2 
1 
1 
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Figure 1.
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Figure 2.  
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Legends of the figures: 
Figure 1. Dual nodal basins drainage. Dynamic images of melanoma in the middle of the 
abdominal wall: upper row - sequential filling from first to fifth image demonstrates drainage 
pathways to the right inguinal region with one sentinel node. The next five sequential images 
(bottom row) shows second basin in right axilla region with one sentinel lymph node and “in 
transit” node (circle).   
 
Figure 2. Primary melanoma on the left shoulder (the largest hot spot). Static (5-minutes 
studies) in anterior (AP), posterior (PA), left (L lateral) and right lateral (R lateral) view 20 
and 25 minutes post injection: lymphatic drainage from primary melanoma of the left 
shoulder to the left supraclavicular (retroclavicular) region and two sentinel nodes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
